Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002GlobeNewsWire • 01/09/24
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceGlobeNewsWire • 12/04/23
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/09/23
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual MeetingGlobeNewsWire • 11/03/23
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC 2023) Annual MeetingGlobeNewsWire • 10/11/23
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic CancerGlobeNewsWire • 09/27/23
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer VaccinesGlobeNewsWire • 09/07/23
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic CancerGlobeNewsWire • 09/05/23
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of BiometricsGlobeNewsWire • 08/28/23
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 08/11/23
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease ModelGlobeNewsWire • 08/09/23
Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual MeetingGlobeNewsWire • 06/03/23
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer VaccinesGlobeNewsWire • 09/20/22
Elicio Therapeutics Presents Preclinical Data on its Lymph Node-Targeted SARS-CoV-2 Amphiphile Vaccine, ELI-005, at the 2022 Keystone Symposia on Viral Immunity: Basic Mechanisms and Therapeutic ApplicationsGlobeNewsWire • 07/06/22
Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in Mutant KRAS-Driven Cancers at ASCO Annual Meeting 2022GlobeNewsWire • 05/27/22
Elicio Therapeutics Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy Enhances Anti-Tumor Function and Eradicates Solid TumorsGlobeNewsWire • 05/23/22
Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven TumorsGlobeNewsWire • 05/16/22
Elicio Therapeutics Announces Appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and Promotion of Dr. Peter DeMuth to Chief Scientific OfficerGlobeNewsWire • 05/12/22
Elicio Therapeutics Moves into Boston's Seaport District and Provides Update on ProgramsGlobeNewsWire • 03/15/22
